» Articles » PMID: 6784774

Uptake and Distribution of Placental Glucocerebrosidase in Rat Hepatic Cells and Effects of Sequential Deglycosylation

Overview
Specialties Biochemistry
Biophysics
Date 1981 Apr 3
PMID 6784774
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The clearance of native human placental glucocerebrosidase by rat liver shows the presence of two distinct enzyme forms with different recognition characteristics. The clearance and uptake of native enzyme by liver cells was compared to that of glucocerebrosidase sequentially treated with neuraminidase, beta-galactosidase and beta-N-acetylglucosaminidase. The initial rate of clearance of infused enzyme was increased greater than 10-fold for the asialo-, agalacto- and ahexoenzymes over that of native glucocerebrosidase. Incorporation of asialo enzyme was increased in hepatocytes over that of native enzyme, while the distribution of agalacto- and ahexoenzyme preparations was increased in non-parenchymal cells. This observation is consistent with the identification of a galactose receptor on hepatocytes and N-acetylglucosamine/mannose receptors on Kupffer cells. These data and inhibition studies by specified monosaccharide-terminal glycoprotein derivatives demonstrate the importance of these sugars in the uptake of this lysosomal enzyme by receptor-mediated endocytosis. Modification of the enzyme to expose certain monosaccharide moieties results in increased delivery to specific cell types. Therefore, naturally occurring receptors can be utilized for targeting glucocerebrosidase to the non-parenchymal cell in liver.

Citing Articles

Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies.

Rocamora F, Peralta A, Shin S, Sorrentino J, Wu M, Toth E Biotechnol Adv. 2023; 67:108206.

PMID: 37354999 PMC: 11168894. DOI: 10.1016/j.biotechadv.2023.108206.


Targeted Enzymatic VLP-Nanoreactors with β-Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease.

Chauhan K, Olivares-Medina C, Villagrana-Escareno M, Juarez-Moreno K, Cadena-Nava R, Rodriguez-Hernandez A ChemMedChem. 2022; 17(19):e202200384.

PMID: 35918294 DOI: 10.1002/cmdc.202200384.


Emerging glyco-based strategies to steer immune responses.

Anderluh M, Berti F, Bzducha-Wrobel A, Chiodo F, Colombo C, Compostella F FEBS J. 2021; 288(16):4746-4772.

PMID: 33752265 PMC: 8453523. DOI: 10.1111/febs.15830.


The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells.

Tian W, Ye Z, Wang S, Schulz M, Van Coillie J, Sun L Nat Commun. 2019; 10(1):1785.

PMID: 31040271 PMC: 6491494. DOI: 10.1038/s41467-019-09809-3.


Genetic disruption of multiple α1,2-mannosidases generates mammalian cells producing recombinant proteins with high-mannose-type -glycans.

Jin Z, Kitajima T, Dong W, Huang Y, Ren W, Guan F J Biol Chem. 2018; 293(15):5572-5584.

PMID: 29475941 PMC: 5900765. DOI: 10.1074/jbc.M117.813030.